Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiota, pharmacogenetics and integrase inhibitor exposure in HIV
2020-001103-17Phase 4Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide, dolutegravir, bictegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Cliniques universitaires Saint-Luc. Primary endpoints: Impact of pharmacogenetic polymorphisms on integrase inhibitor exposure and Impact of gut microbiota on integrase inhibitor exposure. Started Dec 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidedolutegravirbictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-001103-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001103-17.